Regulus Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 32

Employees

  • Stock Symbol
  • RGLS

Stock Symbol

  • Share Price
  • $1.21
  • (As of Friday Closing)

Regulus Therapeutics General Information

Description

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4224 Campus Point Court
  • Suite 210
  • San Diego, CA 92121
  • United States
+1 (888)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4224 Campus Point Court
  • Suite 210
  • San Diego, CA 92121
  • United States
+1 (888)

Regulus Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regulus Therapeutics Stock Performance

As of 14-Feb-2025, Regulus Therapeutics’s stock price is $1.21. Its current market cap is $79.3M with 65.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.21 $1.21 $0.83 - $3.79 $79.3M 65.5M 465K -$1.02

Regulus Therapeutics Financials Summary

As of 30-Sep-2024, Regulus Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 9,001 (1,524) (15,834) 17,373
Revenue 0 0 0 0
EBITDA (44,258) (30,882) (28,117) (27,357)
Net Income (41,628) (30,037) (28,323) (27,808)
Total Assets 93,763 30,750 46,716 68,454
Total Debt 476 2,389 6,279 7,090
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Regulus Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Regulus Therapeutics‘s full profile, request access.

Request a free trial

Regulus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Regulus Therapeutics‘s full profile, request access.

Request a free trial

Regulus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies
Drug Discovery
San Diego, CA
32 As of 2024

Waltham, MA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Regulus Therapeutics Competitors (37)

One of Regulus Therapeutics’s 37 competitors is Viridian Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Viridian Therapeutics Formerly VC-backed Waltham, MA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
Lineage Cell Therapeutics Corporation Carlsbad, CA
Mustang Bio Formerly VC-backed Worcester, MA
You’re viewing 5 of 37 competitors. Get the full list »

Regulus Therapeutics Patents

Regulus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022361062-A1 Methods and compositions for treatment of polycystic kidney disease Pending 08-Oct-2021
AU-2022360530-A1 Methods and compositions for avoiding off-target effects Pending 08-Oct-2021
CA-3233014-A1 Methods and compositions for avoiding off-target effects Pending 08-Oct-2021
CA-3234547-A1 Methods and compositions for treatment of polycystic kidney disease Pending 08-Oct-2021
US-20240294913-A1 Methods and compositions for treatment of polycystic kidney disease Pending 08-Oct-2021 C12N15/113
To view Regulus Therapeutics’s complete patent history, request access »

Regulus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regulus Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Regulus Therapeutics’s complete esg history, request access »

Regulus Therapeutics FAQs

  • When was Regulus Therapeutics founded?

    Regulus Therapeutics was founded in 2007.

  • Where is Regulus Therapeutics headquartered?

    Regulus Therapeutics is headquartered in San Diego, CA.

  • What is the size of Regulus Therapeutics?

    Regulus Therapeutics has 32 total employees.

  • What industry is Regulus Therapeutics in?

    Regulus Therapeutics’s primary industry is Drug Discovery.

  • Is Regulus Therapeutics a private or public company?

    Regulus Therapeutics is a Public company.

  • What is Regulus Therapeutics’s stock symbol?

    The ticker symbol for Regulus Therapeutics is RGLS.

  • What is the current stock price of Regulus Therapeutics?

    As of 14-Feb-2025 the stock price of Regulus Therapeutics is $1.21.

  • What is the current market cap of Regulus Therapeutics?

    The current market capitalization of Regulus Therapeutics is $79.3M.

  • Who are Regulus Therapeutics’s competitors?

    Viridian Therapeutics, Dicerna Pharmaceuticals, Crinetics Pharmaceuticals, Lineage Cell Therapeutics, and Mustang Bio are some of the 37 competitors of Regulus Therapeutics.

  • What is Regulus Therapeutics’s annual earnings per share (EPS)?

    Regulus Therapeutics’s EPS for 12 months was -$1.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »